These endpoints are not quick or easy to measure so perhaps a possibility is surrogate endpoints with conditional licences, almost like a Phase IV [post licensing] trial.???Finding drugs to treat dementia is especially difficult because the brain is relatively inaccessible and harder to test and deliver compounds to, explains Simon Lovestone, a professor of translational neuroscience at the Univer